We demonstrate evidence supporting the efficacy of hydroxocobalamin in reducing vasopressor requirements for LVAD patients with refractory vasoplegia. Further study is needed to substantiate these findings and determine its optimal use in practice.
Keywords: LVAD; cardiac; hydroxocobalamin; vasoplegia; vasoplegic syndrome; ventricular assist device; vitamin B12.
© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.